Further reinforcing its successful growth in providing easily absorbed oral pills that are generally given by injection, Merrion Pharmaceuticals plc, a pharmaceutical development company, today announced that its new state-of-the-art facility in Citywest, CO Dublin has been licensed under the EU Clinical Directive for Investigational Medicinal Products. Inspections conducted by the Irish Medicines Board confirmed the quality, safety and efficacy of medicines developed at the facility.
Designed to most efficiently develop new drug products and manufacture for clinical development, the 30,000 sq. ft pharmaceutical facility was acquired by Merrion in July 2009. The purchase provided the Company with much-needed additional research and development space for the company to undertake its existing workload and to initiate new collaborations and products.
The Irish Medicines Board is responsible for monitoring the quality of medicines by conducting inspections at sites of manufacture and distribution of medicines and by random sampling of products both pre and post authorization. The IMB ensures regulation throughout Ireland and the European Union.
“The granting of this license is another important milestone for Merrion,” said John Lynch, CEO, Merrion Pharmaceuticals, “as it allows us to manufacture for clinical trials. We have a great track record of high-quality standards in rapidly developing and manufacturing products based on our GIPET® technology. The IMB license for our Citywest facility will allow us to expand the number of products we can develop for ourselves and for partners.”
